Pfizer's LORBRENA Study: Majority ALK+ Lung Cancer Patients Live Five Years Disease-Free miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone, resulting in median overall survival of.
An unprecedented 60% of patients remain alive without disease progression after five years
Updated results show continued 81% reduction in risk of progression or death and 94% reduction in.
Pfizer says lung cancer drug Lorbrena could be $1 billion blockbuster qz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from qz.com Daily Mail and Mail on Sunday newspapers.